Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-04-05
2011-04-05
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013300, C514S021800, C530S329000
Reexamination Certificate
active
07919466
ABSTRACT:
Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
REFERENCES:
patent: WO-9950461 (1999-10-01), None
patent: WO 02086113 (2002-10-01), None
patent: WO-03040693 (2003-05-01), None
patent: WO-2005039495 (2005-05-01), None
patent: WO-2007090194 (2007-08-01), None
P. Laakkonen et al. Proc. Natl. Acad. Sci. USA (2004) 101(25), pp. 9381-9386.
Laakkonen P et al. Peptide targeting of tumor lymph vessels. Annals of the NY Academy of Sciences 1131:37-43, 2008.
International Search Report for PCT/US2007/061480 dated Oct. 24, 2007.
Written Opinion for PCT/US2007/061480 dated Jan. 14, 2008.
International Preliminary Report on Patentability for PCT/US2007/061480 dated Aug. 5, 2008.
European Supplemental Search Report for PCT/US2007/061480 dated May 28, 2009.
Kang H. et al. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Research 7:R402-R410, 2005.
Alitalo K et al. Lymphangiogenesis and cancer: meeting report. Cancer Research 64:9225-9229, 2004.
Arap, W., Pasqualini, R., and Ruoslahti, E. (1998). Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 10, 560-565.
Arbeit, J. M., Howley, P. M., and Hanahan, D. (1996). Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 93, 2930-2935.
Arbeit, J. M., Munger, K., Howley, P. M., and Hanahan, D. (1994). Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 68, 4358-4368.
Bae, V. L., Jackson-Cook, C. K., Maygarden, S. J., Plymate, S. R., Chen, J., and Ware, J. L. (1998). Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 34, 275-282.
Borges, E., Jan, Y., and Ruoslahti, E. (2000). Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem 275, 39867-39873.
Brooks, P. G., Clouse, J., and Morris, L. S. (1994). Hysterectomy vs. resectoscopic endometrial ablation for the control of abnormal uterine bleeding. A cost-comparative study. J Reprod Med 39, 755-760.
Cao, R., Bjorndahl, M. A., Religa, P., Clasper, S., Garvin, S., Galter, D., Meister, B., Ikomi, F., Tritsaris, K., Dissing, S., et al. (2004). PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6, 333-345.
Cassella, M., and Skobe, M. (2002). Lymphatic vessel activation in cancer. Ann N Y Acad Sci 979, 120-130.
Chen Y, Xu X, Hong S, Chen J, Liu N, Underhill CB, Creswell K, Zhang L. RGD-Tachyplesin inhibits tumor growth. Cancer Res. Mar. 15, 2001;61(6):2434-8.
Christian, S., Pilch, J., Akerman, M. E., Porkka, K., Laakkonen, P., and Ruoslahti, E. (2003). Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 163, 871-878.
Coussens, L. M., Hanahan, D., and Arbeit, J. M. (1996). Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 149, 1899-1917.
Curnis, F., Gasparri, A., Sacchi, A., Longhi, R., and Corti, A. (2004). Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res 64, 565-571.
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., and Corti, A. (2000). Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18, 1185-1190.
Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., et al. (1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5, 1032-1038.
Ferrara, N., and Alitalo, K. (1999). Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5, 1359-1364.
Giraudo, E., Inoue, M., and Hanahan, D. (2004). An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114, 623-633.
Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.
Helbig, G., Christopherson, K. W., 2nd, Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., and Nakshatri, H. (2003). NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278, 21631-21638.
Hoffman, J. A., Giraudo, E., Singh, M., Zhang, L., Inoue, M., Porkka, K., Hanahan, D., and Ruoslahti, E. (2003). Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4, 383-391.
Hoffman, J., Laakkonen, P., Porkka, K., Bernasconi, M., and Ruoslahti, E (2004). In vivo and ex vivo selections using phage-displayed libraries. in Phage Display: A Practical Approach (Clarkson, T. and Lowman, H., eds.), Oxford University Press, Oxford, U.K.
Hsu, C. X., Ross, B. D., Chrisp, C. E., Derrow, S. Z., Charles, L. G., Pienta, K. J., Greenberg, N. M., Zeng, Z., and Sanda, M. G. (1998). Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol 160, 1500-1505.
Jackson, D. G., Prevo, R., Clasper, S., and Banerji, S. (2001). LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 22, 317-321.
Joyce, J. A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., and Hanahan, D. (2003). Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4, 393-403.
Laakkonen, P., Akerman, M. E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R. M., and Ruoslahti, E. (2004). Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A 101, 9381-9386.
Laakkonen, P., Porkka, K., Hoffman, J. A., and Ruoslahti, E. (2002). A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8, 751-755.
Lin, J., Lalani, A. S., Harding, T. C., Gonzalez, M., Wu, W. W., Luan, B., Tu, G. H., Koprivnikar, K., VanRoey, M. J., He, Y., et al. (2005). Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65, 6901-6909.
Mandriota, S. J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J., Montesano, R., Jackson, D. G., et al. (2001). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. Embo J 20, 672-682.
Mouta Carreira, C., Nasser, S. M., di Tomaso, E., Padera, T. P., Boucher, Y., Tomarev, S. I., and Jain, R. K. (2001). LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 61, 8079-8084.
Nagasawa, T., Kikutani, H., and Kishimoto, T. (1994). Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A 91, 2305-2309.
Padera, T. P., Kadambi, A., di Tomaso, E., Carreira, C. M., Brown, E. B., Boucher, Y., Choi, N. C., Mathisen, D., Wain, J., Mark, E. J., et al. (2002). Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883-1886.
Pasqualini, R., Koivunen, E., Kain, R., Landenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R. A., Shapiro, L. H., Arap, W., and Ruoslahti, E. (2000). Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60, 722-727.
Ruoslahti, E. (2002). Specialization of tumour vasculature. Nat Rev Cancer 2, 83-90.
Ruoslahti, E. (2003). The RGD story: a personal account. Matrix Biol 22, 459-465.
Saharinen, P., Tammela, T., Karkkainen, M. J., and Alitalo, K. (2004). Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25, 387-395.
Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., Ricca
Hanahan Douglas
Ruoslahti Erkki
Zhang Lianglin
Kosar Andrew D
Pabst Patent Group LLP
Sanford-Burnham Medical Research Institute
The Regents of the University of California
LandOfFree
Lymphatic zip codes in tumors and pre-malignant lesions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lymphatic zip codes in tumors and pre-malignant lesions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphatic zip codes in tumors and pre-malignant lesions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2728909